NICE Gives Final Guidance on Cimzia and Cosentyx

The National Institute for Health and Care Excellence (NICE) has published a final guidance supporting the use of Cimzia (certolizumab pegol) and Cosentyx (secukinumab) for treatment of active psoriatic arthritis alone or in combination with methotrexate in specified circumstances.

The recommendation for use by the National Health Service is contingent on keeping the cost low through patient access schemes.